REMS Program Resources for Clinicians

EP: 1.Role of Small-Molecule Myosin Inhibitors in oHCM Treatment

EP: 2.Unmet Needs in oHCM Care

EP: 3.Using Cardiac Myosin Inhibitors for the Treatment of oHCM

EP: 4.Clinical Trial Outcomes for Cardiac Myosin Inhibitors in oHCM Treatment

EP: 5.Role of Mavacamten in Treating oHCM

Now Viewing

EP: 6.REMS Program Resources for Clinicians

This is a video synopsis of a discussion involving James L. Januzzi, MD, regarding the importance of healthcare providers and pharmacists educating themselves about the Risk Evaluation and Mitigation Strategy (REMS) program before initiating mavacamten (cardiac myosin inhibitor) therapy for hypertrophic cardiomyopathy (HCM). Preparation is crucial to understand the REMS program's requirements, which can be found on the website of the United States Food and Drug Administration and through resources provided by the drug manufacturer.

Effective coordination with colleagues, especially in the cardiac ultrasound lab, is essential to seamlessly schedule patients and ensure timely follow-up for echocardiograms every four weeks initially and every 12 weeks thereafter. Despite its complexity, institutions like the Massachusetts General Hospital Heart Center have successfully implemented the REMS program, improving safety and patient outcomes.

While navigating the REMS program may be more intricate, its effectiveness in enhancing safety and patient well-being is undeniable. Patient feedback underscores the significant improvement in symptoms and quality of life experienced with mavacamten therapy, highlighting the program's value in managing HCM effectively and safely.

Video synopsis is AI-generated and reviewed by HCPLive® editorial staff.